Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
You need to sign in or sign up before continuing.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can the Moderna and BioNTech Bulls Keep Running?


Positive results from clinical trials with their coronavirus vaccine candidates have pushed shares of Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) into the clouds. Neither of these companies has developed a marketable product yet, but their market caps have risen to a combined $62 billion at recent prices.

With plenty of competition on the way, neither of these companies can justify their recent stock-market valuations with potential sales from just one coronavirus vaccine. Can these companies be expected to produce multiple blockbuster drugs? Here's what you need to know about the road ahead for Moderna, BioNTech, and a wave of younger businesses developing similar drugs.

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments